BiondVax Presenting at BIO CEO & Investor Conference
02 Febbraio 2023 - 8:15PM
via InvestorWire – BiondVax Pharmaceuticals
Ltd. (Nasdaq: BVXV), a biotechnology company focused on
developing, manufacturing, and commercializing innovative
immunotherapeutic products primarily for the treatment of
infectious and autoimmune diseases, announced today that its CEO
Amir Reichman will present at the BIO CEO & Investor
Conference. The conference is taking place Feb. 6-9, 2023, in New
York.
Reichman’s presentation will focus on recent
successful preclinical in vivo results of BiondVax’s innovative
inhaled COVID-19 treatment and additional pipeline plans, including
nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune
diseases, such as psoriasis, asthma, psoriatic arthritis and
macular degeneration. BiondVax’s de-risked R&D strategy
includes generating a pipeline of biobetter NanoAbs aimed at
molecular targets validated by currently approved monoclonal
antibodies (mAbs) addressing diseases with underserved medical
needs and attractive commercial opportunities.
Details of BiondVax’s presentation are as follows:
- Date: Monday, Feb. 6, 2023
- Time: 4:15 p.m. (ET)
- Location: Winter Garden Room, New York Marriott Marquis
Reichman and Mark Germain, BiondVax’s chairman
of the board, will be available to meet potential partners,
collaborators and investors. Parties registered for the conference
are encouraged to schedule one-to-one appointments via the
Biotechnology Innovation Organization (BIO) partnering platform at
https://www.partnering.bio.org/ceo2023. Alternatively, parties
interested in meeting with Reichman and Germain may contact the
Company directly at the contact information below.
About BiondVaxBiondVax Pharmaceuticals
Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on
developing, manufacturing, and commercializing innovative
immunotherapeutic products primarily for the treatment of
infectious and autoimmune diseases. Since its inception, BiondVax
has executed eight clinical trials including a seven-country,
12,400-participant Phase 3 trial of its prior vaccine candidate and
has built a state-of-the-art manufacturing facility for
biopharmaceutical products. With highly experienced pharmaceutical
industry leadership, BiondVax is aiming to develop a pipeline of
diversified and commercially viable products and platforms
beginning with an innovative nanosized antibody (NanoAb) pipeline.
www.biondvax.com.
Contact DetailsJoshua E Phillipson | +972 8 930 2529 |
j.phillipson@biondvax.com
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Litigation Reform Act
of 1995. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements. All
statements, other than statements of historical facts, included in
this communication regarding strategy, future operations, future
financings, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, acquiring an additional license from Max
Planck for the therapeutic and commercial potential of nanosized
antibodies (NanoAbs); and the timing of NanoAb proof-of-concept
studies and clinical trials and the necessary steps needed for such
studies and trials. These forward-looking statements reflect
management’s current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals Ltd.
Risks and uncertainties include, but are not limited to, the risk
that we may not a second NanoAb license from Max Planck for a
NanoAb targeting IL-17 as a treatment for psoriasis, the risk of a
delay in proof-of-concept studies and the commencement of clinical
trials for NanoAbs, if any, and delays in the necessary steps
needed for such studies and trials; the risk that the therapeutic
and commercial potential of NanoAbs will not be met; the risk that
clinical trials relating to NanoAbs will fail in whole or in part;
the risk that BiondVax may not be able to secure additional capital
on attractive terms, if at all; risks relating to the COVID-19
(coronavirus) pandemic; BiondVax’s ability to acquire rights to
additional product opportunities; BiondVax’s ability to enter into
collaborations on terms acceptable to BiondVax or at all; timing of
receipt of regulatory approval of BiondVax’s manufacturing facility
in Jerusalem, if at all or when required; the risk that the
manufacturing facility will not be able to be used for a wide
variety of applications and other vaccine and treatment
technologies, and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading “Risk Factors” in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission on March 28, 2022. BiondVax undertakes no obligation to
revise or update any forward-looking statement for any reason.
Corporate Communications:InvestorBrandNetwork (IBN)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Giu 2023 a Giu 2024